NR1H4 and obesity due to melanocortin 4 receptor deficiency: FXR activators have been successfully applied for treatment of dyslipidemia, insulin resistance, and steatosis in obesity, diabetes, alcohol-induced liver injury, and non-alcohol fatty liver or steatohepatitis [5,6,7].